Search - tctmd.com

Displaying 541 - 560 of 1009

Sort: Relevancy | Date

News Daily News

Aborted TAVR Procedures Are Waning in the US

Shelley Wood

August 28, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Daily News

Substantial Increase in PCI Survival Over 10 Years: Single Center

Yael L. Maxwell

August 16, 2019

News Daily News

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

Caitlin E. Cox

August 12, 2019

News Daily News

Stroke After PCI: Rare but Rising as Patient Complexity Climbs

Todd Neale

August 05, 2019

News Daily News

Trial Points to Possible Benefit of Intensive BP-Lowering to Stave Off Recurrent Stroke

Todd Neale

July 29, 2019

News Daily News

FDA Grants Cardiac MR Indication for Gadavist Contrast Injection

Shelley Wood

July 16, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Industry News

Health Library: Hypertension (High Blood Pressure)

June 24, 2019

News Featured Fellow

Amir Azarbal, MD

Yael L. Maxwell

June 20, 2019

Presentation TVT 2019

Ferumoxytol Enhanced MRA for Transcatheter Aortic Valve Replacement Planning in Patients With Chronic Kidney Disease

Presenter: Anjali Sharma

June 14, 2019

News Daily News

TAVR in End-stage Renal Disease: Increased Risk Highlights Research Gaps

Yael L. Maxwell

June 11, 2019

News Conference News EuroPCR 2019

Small Study Lends Further Support to the Antiarrhythmic Potential of Renal Denervation

L.A. McKeown

June 06, 2019

News Conference News SCAI 2019

ProGlide Comes Out Ahead of Prostar in Vascular Closure After Transfemoral TAVR: BRAVO 3

Yael L. Maxwell

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

News Conference News ESC Heart Failure 2019

Device-Based Therapy Offers REPRIEVE From Decongestion in Acute HF: TARGET 1 and 2

Shelley Wood

May 25, 2019

News Industry News

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

May 13, 2019

Advertisement

Aborted TAVR Procedures Are Waning in the US

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Substantial Increase in PCI Survival Over 10 Years: Single Center

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

Stroke After PCI: Rare but Rising as Patient Complexity Climbs

Trial Points to Possible Benefit of Intensive BP-Lowering to Stave Off Recurrent Stroke

FDA Grants Cardiac MR Indication for Gadavist Contrast Injection

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Health Library: Hypertension (High Blood Pressure)

Amir Azarbal, MD

Ferumoxytol Enhanced MRA for Transcatheter Aortic Valve Replacement Planning in Patients With Chronic Kidney Disease

TAVR in End-stage Renal Disease: Increased Risk Highlights Research Gaps

Small Study Lends Further Support to the Antiarrhythmic Potential of Renal Denervation

ProGlide Comes Out Ahead of Prostar in Vascular Closure After Transfemoral TAVR: BRAVO 3

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

CHD Mortality Significantly Elevated in Patients With Severe FH

New Clarity on Patients at High Risk for Bleeding After PCI

Device-Based Therapy Offers REPRIEVE From Decongestion in Acute HF: TARGET 1 and 2

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content